Complementary and alternative medicine (CAM) treatments and pediatric psychopharmacology

Journal of the American Academy of Child and Adolescent Psychiatry

Volumn 47, Issue 4, 2008, Pages 364-368

  Rey, Joseph M ^a,c   Walter, Garry ^a   Soh, Nerissa ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b Child and Adolescent Mental Health Services

^c NONE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CARBAMAZEPINE; CITALOPRAM; CYCLOSPORIN; DIGOXIN; EPHEDRA EXTRACT; FLUOXETINE; FLUVOXAMINE; HERBACEOUS AGENT; HYPERICUM PERFORATUM EXTRACT; INDINAVIR; KAVA EXTRACT; NELFINAVIR; OMEGA 3 FATTY ACID; ORAL CONTRACEPTIVE AGENT; PAROXETINE; PASSIFLORA INCARNATA EXTRACT; PHENYTOIN; PROTEINASE INHIBITOR; RAUWOLFIA EXTRACT; RESERPINE; S ADENOSYLMETHIONINE; SECRETIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TACROLIMUS; THEOPHYLLINE; UNINDEXED DRUG; WARFARIN;

ALTERNATIVE MEDICINE; ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; AUTISM; AUTOMUTILATION; BIPOLAR DISORDER; BREAKTHROUGH BLEEDING; CHILDHOOD DISEASE; DEPRESSION; DEVELOPMENTAL DISORDER; DIET SUPPLEMENTATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; EPHEDRA; GRAFT REJECTION; HUMAN; HYPERICUM PERFORATUM; MENTAL DISEASE; MOOD DISORDER; PRIORITY JOURNAL; RAUWOLFIA; REVIEW; SCHIZOPHRENIA; UNSPECIFIED SIDE EFFECT;

EID: 41349093603     PISSN: 08908567     EISSN: None     Source Type: Journal    
DOI: 10.1097/CHI.0b013e31816520e5     Document Type: Article

References (23)

1. Wilson KM, Klein JD, Sesselberg TS, et al. Use of complementary medicine and dietary supplements among US adolescents. J Adolesc Health. 2006;38:385-394.
2. Fegert JM, Kolch M, Zito JM, Glaeske G, Janhsen K. Antidepressant use in children and adolescents in Germany. J Child Adolesc Psychopharmacol. 2006;16:197-206.
3. Kemper KJ, O'Connor KG. Pediatricians' recommendations for complementary and alternative medical (CAM) therapies. Ambul Pediatr. 2004;4:482-487.
4. Lopez-Munoz F, Bhatara VS, Alamo C, Cuenca E. Historical approach to reserpine discovery and its introduction in psychiatry. Actas Esp Psiquiatr. 2004;32:387-395.
5. Dennehy CE, Tsourounis C, Horn AJ. Dietary supplement-related adverse events reported to the California Poison Control System. Am J Health Syst Pharm. 2005;62:1476-1482.
6. Freeman MP, Hibbeln JR, Mischoulon D, et al. Omega-3 fatty acids: evidence for treatment and future research in psychiatry. J Clin Psychiatry. 2006;67:1954-1967.
7. Clayton EH, Hanstock TL, Garg ML, Hazell PL. Long chain omega-3 polyunsaturated fatty acids in the treatment of psychiatric illnesses in children and adolescents. Acta Neuropsychiatr. 2007;19:92-103.
8. Jorm AF, Allen NB, O'Donnell CP, Parslow RA, Purcell R, Morgan AJ. Effectiveness of complementary and self-help treatments for depression in children and adolescents. Med J Aust. 2006;185:368-372.
9. Linde K, Berner M, Egger M, Mulrow C. St. John's wort for depression. Meta-analysis of randomized controlled trials. Br J Psychiatry. 2005;186: 99-107.
10. Ernst E. Second thoughts about safety of St. John's wort. Lancet. 1999;354:2014-2016.
11. Mischoulon D. Update and critique of natural remedies as antidepressant treatments. Psychiatr Clin North Am. 2007;30:51-68.
12. Pittler MH, Ernst E. Kava extract versus placebo for treating anxiety. Cochrane Database Syst Rev 2003;1: CD003383.
13. Centers for Disease Control and Prevention. Hepatic toxicity possibly associated with kava-containing products - United States, Germany and Switzerland 1999-2002. MMWR Morb Mortal Wkly Rep. 2002;51: 1065Y1067.
14. Levy SE, Hyman SL. Novel treatments for autistic spectrum disorders. Ment Retard Dev Disabil Res Rev. 2005;11:131-142.
15. Jorm AF, Christensen H, Griffiths KM, Parslow RA, Rodgers B, Blewitt KA. Effectiveness of complementary and self-help treatments for anxiety disorders. Med J Aust. 2004;181:S29-S46.
16. Akhondzadeh S, Naghavi HR, Vazirian M, et al. Passionflower in the treatment of generalized anxiety: a pilot double-blind randomized controlled trial with oxazepam. J Clin Pharm Ther. 2001;26: 363-367.
17. Cohen MH, Kemper KJ. Complementary therapies in pediatrics: a legal perspective. Pediatrics. 2005;115:774-781.
18. Nemets H, Nemets B, Apter A, Bracha Z, Belmaker RH. Omega-3 treatment of childhood depression: a controlled, double-blind pilot study. Am J Psychiatry. 2006;163:1098-1100.
19. Joy CB, Mumby-Croft R, Joy LA. Polyunsaturated fatty acid supplementation for schizophrenia. Cochrane Database Syst Rev 2006;3: CD001257.
20. Hallaham B, Hibbeln JR, Davis JM, Garland MR. Omega-3 fatty acid supplementation in patients with recurrent self-harm. Single-centre double-blind randomized controlled trial. Br J Psychiatry. 2007; 190:118-122.
21. Richardson AJ, Montgomery P. The Oxford-Durham Study: a randomized, controlled trial of dietary supplementation with fatty acids in children with developmental coordination disorder. Pediatrics. 2005;115:1360-1366.
22. Amminger GP, Berger GE, Schafer MR, Klier C, Friedrich MH, Feucht M. Omega-3 fatty acids supplementation in children with autism: a double-blind randomized, placebo-controlled pilot study. Biol Psychiatry. 2006;61:551-553.
23. Mosca L, Banka CL, Benjamin EJ, et al. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. J Am Coll Cardiol. 2007;49:1230-1250.